Characteristics of HSCT recipients
| Subject . | Genotype . | Transplant indications . | Sex . | Age at HSCT, y . | Pre-HSCT Hb, g/dL . | Pre-HSCT Hb S, % . | Donor, stem cell source, genotype . | Post-HSCT Hb, g/dL . | Post-HSCT Hb S, % . | Myeloid engraftment, % donor . |
|---|---|---|---|---|---|---|---|---|---|---|
| A∗ | Hb S-β+ | ACS, TCD (no SCI), CRTT | M | 6.5 | 8.4 | 41.6 | MSD, PBSCs, AS | 11.7 | 40.7 | 95 |
| B | Hb SS | ACS, SCI, CRTT | M | 7.7 | 9.5 | 49.9 | MSD, marrow, AS | 12.3 | 39.7 | 62 |
| C | Hb SS | VOE, SCI | F | 9.5 | 10.1 | 77.6 | MSD, marrow, AS | 12.5 | 26.8 | 100 |
| D | Hb SS | ACS, TCD, SCI, sickle hepatopathy, CRTT | M | 11.0 | 8.6 | 25.3 | MSD, marrow, AA | 12.4 | 0 | 70 |
| E | Hb SS | TCD, cerebral vasculopathy, SCI, HSCT rejection, CRTT | F | 11.5 | 10.0 | 35.9 | MSD, PBSCs, AS | 12.2 | 41.5 | 66 |
| F | Hb SS | VOE, HSCT rejection | F | 11.7 | 7.5 | 51.5 | MSD, PBSCs, AS | 11.3 | 35.6 | 65 |
| G∗ | Hb S-β+ | ACS, VOE, SCI, autoimmune hemolytic anemia | M | 12.4 | 7.1 | 82.0 | MSD, PBSCs, AS | 11.8 | 40.8 | 100 |
| H | Hb SS | Overt stroke, CRTT | F | 16.6 | 7.4 | 74.2 | MUD, marrow, AA | 13.6 | 0 | 97 |
| I | Hb S-β+ | ACS, VOE, SCI, overt stroke, CRTT | M | 19.0 | 12.9 | 34.0 | MUD, marrow, AA | 16.7 | 0 | 92 |
| J | Hb SS | Overt stroke, CRTT | M | 21.6 | 11.5 | 39.7 | MUD, marrow, AA | 15.7 | 0 | 100 |
| Subject . | Genotype . | Transplant indications . | Sex . | Age at HSCT, y . | Pre-HSCT Hb, g/dL . | Pre-HSCT Hb S, % . | Donor, stem cell source, genotype . | Post-HSCT Hb, g/dL . | Post-HSCT Hb S, % . | Myeloid engraftment, % donor . |
|---|---|---|---|---|---|---|---|---|---|---|
| A∗ | Hb S-β+ | ACS, TCD (no SCI), CRTT | M | 6.5 | 8.4 | 41.6 | MSD, PBSCs, AS | 11.7 | 40.7 | 95 |
| B | Hb SS | ACS, SCI, CRTT | M | 7.7 | 9.5 | 49.9 | MSD, marrow, AS | 12.3 | 39.7 | 62 |
| C | Hb SS | VOE, SCI | F | 9.5 | 10.1 | 77.6 | MSD, marrow, AS | 12.5 | 26.8 | 100 |
| D | Hb SS | ACS, TCD, SCI, sickle hepatopathy, CRTT | M | 11.0 | 8.6 | 25.3 | MSD, marrow, AA | 12.4 | 0 | 70 |
| E | Hb SS | TCD, cerebral vasculopathy, SCI, HSCT rejection, CRTT | F | 11.5 | 10.0 | 35.9 | MSD, PBSCs, AS | 12.2 | 41.5 | 66 |
| F | Hb SS | VOE, HSCT rejection | F | 11.7 | 7.5 | 51.5 | MSD, PBSCs, AS | 11.3 | 35.6 | 65 |
| G∗ | Hb S-β+ | ACS, VOE, SCI, autoimmune hemolytic anemia | M | 12.4 | 7.1 | 82.0 | MSD, PBSCs, AS | 11.8 | 40.8 | 100 |
| H | Hb SS | Overt stroke, CRTT | F | 16.6 | 7.4 | 74.2 | MUD, marrow, AA | 13.6 | 0 | 97 |
| I | Hb S-β+ | ACS, VOE, SCI, overt stroke, CRTT | M | 19.0 | 12.9 | 34.0 | MUD, marrow, AA | 16.7 | 0 | 92 |
| J | Hb SS | Overt stroke, CRTT | M | 21.6 | 11.5 | 39.7 | MUD, marrow, AA | 15.7 | 0 | 100 |
F, female; Hb SS, hemoglobin SS disease; Hb S-β+, hemoglobin S-β+ thalassemia; M, male; PBSCs: peripheral blood stem cells; VOE, vaso-occlusive pain event.
Full siblings.